VectivBio (NASDAQ:VECT) Rating Lowered to Neutral at Credit Suisse Group

Credit Suisse Group downgraded shares of VectivBio (NASDAQ:VECT – Get Rating) from an outperform rating to a neutral rating in a research note released on Monday morning, The Fly reports.

Separately, Piper Sandler raised their price objective on VectivBio from $23.00 to $25.00 and gave the company an overweight rating in a report on Thursday, April 20th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $24.33.

VectivBio Price Performance

Shares of NASDAQ VECT opened at $16.34 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.14 and a quick ratio of 9.14. VectivBio has a 1-year low of $4.25 and a 1-year high of $16.63. The stock’s 50-day moving average is $10.27 and its 200 day moving average is $9.00.

Institutional Investors Weigh In On VectivBio

A number of large investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its position in shares of VectivBio by 6.9% in the 1st quarter. Geode Capital Management LLC now owns 24,647 shares of the company’s stock worth $212,000 after buying an additional 1,593 shares during the last quarter. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of VectivBio in the 1st quarter valued at approximately $478,000. Bank of America Corp DE lifted its stake in shares of VectivBio by 805.7% in the 1st quarter. Bank of America Corp DE now owns 39,741 shares of the company’s stock valued at $338,000 after purchasing an additional 35,353 shares during the period. Regency Capital Management Inc. DE purchased a new position in shares of VectivBio in the 1st quarter valued at approximately $323,000. Finally, VR Adviser LLC purchased a new position in shares of VectivBio in the 4th quarter valued at approximately $16,169,000. 90.52% of the stock is currently owned by institutional investors.

VectivBio Company Profile

(Get Rating)

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy.